First-line zanidatamab–chemotherapy with or without tislelizumab improves survival in advanced-stage HER2+ GEA

Nature Reviews Clinical Oncology 2026

View at publisher

Authors: Diana Romero

DOI: 10.1038/s41571-026-01169-4

Cited by: 1

References: 1

Fields of Study & Subjects

HER2/EGFR in Cancer Research Peptidase Inhibition and Analysis Cancer Immunotherapy and Biomarkers

References 1